We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01550484
Recruitment Status : Completed
First Posted : March 12, 2012
Last Update Posted : February 9, 2017
Information provided by (Responsible Party):
Avid Radiopharmaceuticals

March 6, 2012
March 12, 2012
February 9, 2017
April 2012
March 2016   (Final data collection date for primary outcome measure)
  • Sensitivity of visual read of AV-133 PET scan vs. standard of truth [ Time Frame: 18 months ]

    Sensitivity will be calculated as the percent of true positives which are correctly identified

    An expert, consensus diagnosis of PD performed by a panel of movement disorders specialists will be used as the standard of truth.

  • Specificity of visual read of AV-133 PET scan vs. standard of truth [ Time Frame: 18 months ]

    Specificity will be calculated as the percent of true negatives which are correctly identified.

    An expert, consensus diagnosis of PD performed by a panel of movement disorders specialists will be used as the standard of truth.

Same as current
Complete list of historical versions of study NCT01550484 on ClinicalTrials.gov Archive Site
  • Inter-rater reliability of the visual read [ Time Frame: 18 months ]
    Fleiss' kappa
  • Intra-rater reliability of the visual read [ Time Frame: 18 months ]
    Intra-class kappa
  • Probability of progressive motor skill impairment [ Time Frame: 18 months ]
    Compare rates of progressive impairment using PD rating scale in subjects with positive AV-133 PET scan vs. progressive impairment in subjects with negative AV-133 PET scan
Same as current
Not Provided
Not Provided
A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis
The purpose of this study is to determine whether 18F-AV-133 PET scans can be used to differentiate subjects with Parkinson's Disease from other movement disorders.
The early detection and monitoring of neurodegenerative diseases including Parkinson's disease (PD), Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), and other dementias and movement disorders represent a very significant unmet medical need. Disease mechanisms are gradually becoming understood, and disease-modifying drugs are emerging that target the specific molecular pathology underlying each of these diseases. Tools for accurate and early differential diagnosis are thus necessary to determine the appropriate treatment for patients and to minimize inappropriate use of potentially harmful treatments. In addition, such diagnostic imaging tools are expected to permit monitoring of disease progression and will thus accelerate testing and development of disease-modifying drugs. Furthermore, the new imaging test may be useful as a prognostic tool by identifying humans suffering from neurodegenerative diseases before the clinical manifestations become evident.
Phase 2
Phase 3
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
  • Parkinson's Disease
  • Primary Parkinsonism
  • Lewy Body Parkinson's Disease
Drug: 18F-AV-133
222 MBq (6 mCi)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2016
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males or females ≥ 40 years of age;
  • Presenting (within the last 3 months) for an initial evaluation to a movement disorders specialist with signs or symptoms suggestive of a movement disorder;
  • The subject's signs or symptoms were previously evaluated by a physician who was not a movement disorders specialist during the previous six months;
  • Absence of an established clinical movement disorder diagnosis;
  • Symptoms mild in intensity, this includes Hoehn & Yahr ≤ 2 (Exceptions are allowed for subjects who meet criteria for Hoehn & Yahr stage 3 due to early onset of postural instability and/or gait impairment out of proportion to his/her other Parkinson signs and symptoms);
  • Montreal Cognitive Assessment (MoCA) score ≥ 22;
  • Can tolerate imaging visit procedures; and
  • Provide written informed consent prior to study entry.

Exclusion Criteria:

  • Have been referred to the movement disorders clinic primarily for the purpose of disease management (no diagnostic uncertainty exists on the part of the non-specialist or referring physician);
  • Have a previous movement disorder diagnosis given by a movement disorders specialist prior to the time of enrollment;
  • Have received a total of more than 90 days treatment with dopaminergic medications, including direct dopamine agonists or precursors (levodopa) or have received a total of more than 180 days treatment with MAO-B inhibitors, amantadine, anticholinergics or primidone or beta-blockers prescribed for treatment of tremor or signs of parkinsonism;
  • Have had a sustained and clinically meaningful response to anti-parkinsonian medications;
  • Are currently taking or have taken MAO-B inhibitors in the past 4 weeks;
  • Have a known CNS structural lesion such as stroke or tumor that likely accounts for their symptoms;
  • Have clinically meaningful cognitive impairment or dementia (mild cognitive problems as might be expected in the earliest stages of PD are not exclusionary);
  • Have current clinically significant cardiovascular disease or clinically important abnormalities on screening ECG (including but not limited to QTc > 450 msec);
  • Are currently taking medications that are known to cause QT-prolongation;
  • Are currently taking medications with narrow therapeutic windows (e.g. warfarin or other anticoagulant therapies);
  • Are currently taking tetrabenazine (TBZ), amphetamine type drugs;
  • Have a current clinically significant endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer (excluding localized basal cell carcinoma and in situ prostate cancer) that would interfere with completion of the study;
  • Have a recent history (within the past year) of alcohol or substance abuse or dependence;
  • Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable contraception. Females must not be pregnant (negative serum beta-hCG at the time of screening and negative urine beta-hCG on the day of imaging), must not be breastfeeding at screening, must avoid becoming pregnant and use adequate contraceptive methods for 14 days prior to and 24 hours after administration of 18F-AV-133 for injection;
  • Have had prior intracranial surgery; and
  • Are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days.
Sexes Eligible for Study: All
40 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Australia,   United States
Not Provided
Not Provided
Avid Radiopharmaceuticals
Avid Radiopharmaceuticals
Not Provided
Study Director: Chief Medical Officer Avid Radiopharmaceuticals
Avid Radiopharmaceuticals
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP